Cytek Biosciences SVP of Global Sales resigns

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Figures

Key Terms

What executive change did Cytek Biosciences (CTKB) disclose in this 8-K?

When does Philippe Busque’s resignation from Cytek Biosciences (CTKB) take effect?

Did Cytek Biosciences (CTKB) report any disagreement behind the SVP’s resignation?

What role did Philippe Busque hold at Cytek Biosciences (CTKB) before resigning?

Who signed the Cytek Biosciences (CTKB) 8-K reporting the resignation?

Cytek Biosciences, Inc. reported that Philippe Busque, Ph.D. has submitted his resignation as Senior Vice President, Global Sales and Services.

Accepted by SEC EDGAR 06/02/2026 - 04:15 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Cytek Biosciences, Inc. reported that Philippe Busque, Ph.D. has submitted his resignation as Senior Vice President, Global Sales and Services. His resignation is effective June 5, 2026 and is described as being to pursue another career opportunity, with no disagreements regarding the company’s operations, policies or practices.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Resignation submission date: May 27, 2026 Resignation effective date: June 5, 2026 8-K signature date: June 2, 2026

3 metrics

Resignation submission date May 27, 2026 Date Philippe Busque submitted his resignation

Resignation effective date June 5, 2026 Effective date of departure as SVP, Global Sales and Services

8-K signature date June 2, 2026 Date the report was signed by the CEO

Emerging growth company, Nasdaq Global Select Market, Section 13 or 15(d) of the Securities Exchange Act of 1934

3 terms

Emerging growth company regulatory

"Emerging growth company On May 27, 2026, Philippe Busque, Ph.D. submitted his resignation"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Nasdaq Global Select Market financial

"Common Stock, par value $0.001 per share | | CTKB | | Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

Section 13 or 15(d) of the Securities Exchange Act of 1934 regulatory

"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Cytek Biosciences disclosed that Philippe Busque, Ph.D. resigned as Senior Vice President, Global Sales and Services. His departure is presented as a career move and not related to disagreements over company operations, policies, or practices.

Philippe Busque’s resignation as Senior Vice President, Global Sales and Services becomes effective June 5, 2026. He submitted his resignation on May 27, 2026, providing a brief transition period before his departure date.

Cytek Biosciences stated that Philippe Busque’s resignation is not due to any disagreement with the company’s operations, policies or practices. The filing characterizes the move as a decision to pursue another career opportunity rather than a conflict-driven departure.

Before resigning, Philippe Busque, Ph.D. served as Senior Vice President, Global Sales and Services at Cytek Biosciences. The position oversaw global sales and services activities, making it an important commercial leadership role within the company’s organizational structure.

The 8-K was signed on behalf of Cytek Biosciences by Wenbin Jiang, Ph.D., the company’s President and Chief Executive Officer. His signature confirms the company’s authorization and certification of the disclosed executive leadership change and related details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 27, 2026

Cytek Biosciences, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-40632	47-2547526
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


47215 Lakeview Boulevard
Fremont, California		94538
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 922-9835

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	CTKB	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 27, 2026, Philippe Busque, Ph.D. submitted his resignation from his position as the Senior Vice President, Global Sales and Services of Cytek Biosciences, Inc. (the “Company”), effective as of June 5, 2026, to pursue another career opportunity. Dr. Busque’s resignation is not due to any disagreement with the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Cytek Biosciences, Inc.

Date: June 2, 2026

/s/ Wenbin Jiang

Wenbin Jiang, Ph.D.

President and Chief Executive Officer

3 documents